Georgia CEAL RESTORES Family Diabetes Study
Morehouse School of Medicine · with National Heart, Lung, and Blood Institute (NHLBI) · NCT07808723
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 12+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- August 29, 2026
- Record last updated
- September 18, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to determine whether a family-based lifestyle intervention reduces the risk of type 2 diabetes (T2D) among parents and their children. The intervention will also evaluate how well the program supports healthy lifestyle behaviors and family engagement.
The primary outcome of this study is weight loss in parents.
Researchers will evaluate changes in participants' weight and lifestyle behaviors before the study compared to the end of the study (12 weeks post intervention) and 3 months after participation in the program.
Being studied: Family Diabetes Prevention
Conditions: Weight Reduction; Prediabetes
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Parent/guardian must identify as African American or Hispanic
- Parent/guardian must be 18+ years residing in the same household as the child (i.e., biological or have legal guardianship for child)
- Parent/guardian must have prediabetes (HbA1c level 5.7-6.4%) or be at risk of developing Type 2 diabetes using CDC's Pre-Diabetes Risk Test
- Participant is willing to commit to participation in a 12-week, in-person, intervention study
- No plans to move over the next 9-months
- Parent/guardian should be ambulatory and able to participate in physical activity
- Children must be between the ages of 12-17 years old
- Child should be ambulatory and able to participate in physical activity
Exclusion Criteria
- Severe psychological disorders that may prevent/interfere with study -participation
- Physical impairments that may prevent participation in moderate intensity physical activity
- Previous diagnosis of diabetes
- History of congestive heart failure
- Renal failure
- Recent (\<12 months) cardiovascular events such as myocardial infarction (heart attack) or stroke
- Taking medications that may affect endpoint analyses
- Have co-morbid contraindications to physical activity or dietary changes
- Currently pregnant or planning to become pregnant in the next year
- Family lives outside of Georgia
Recruiting US locations
Morehouse School of Medicine
Atlanta, GA 30310
Site contact: Katrina M Brantley, DrPH · 470-670-7840 · kbrantley@msm.edu
Study contacts (from the official record)
- Katrina M Brantley, DrPH · 470-670-7840 · kbrantley@msm.edu
- Danielle M Duvernay, MSHI · 404-756-1224 · dduvernay@msm.edu
Similar studies in Georgia
All weight loss studies in Georgia →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Atlanta, GA + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Canton, GA + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Roswell, GA + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Columbus, GA + 13 other US sites
- Eligibility basics
- Ages 10–18